Vivozon: "VVZ-2471 Shows Analgesic Efficacy Trend in High-Dose Group in Phase 2 Trial"
Oral Analgesic Candidate with Dual Mechanism of Action
"High-Dose Group Shows Greater Pain Reduction and Higher Responder Rate"
On July 6, Vivogen, an affiliate of Vivozon Pharmaceutical, announced that it had observed a trend of analgesic efficacy centered on the high-dose group in the Phase 2 clinical trial of its oral non-narcotic analgesic candidate, VVZ-2471.
VVZ-2471 is an oral non-narcotic analgesic candidate derived from a multi-target new drug development platform technology. It features a dual mechanism of action that simultaneously modulates the metabotropic glutamate receptor (mGluR5) and serotonin receptor 2A (5-HT2A). The candidate was biologically and chemically derived from Anaprazu, which has already demonstrated analgesic efficacy.
This trial was a randomized, double-blind, placebo-controlled Phase 2 clinical study designed to evaluate the exploratory analgesic efficacy and safety of VVZ-2471. Patients with postherpetic neuralgia were assigned to either the VVZ-2471 150 mg group, the 100 mg group, or the placebo group. The primary endpoint was the change in pain intensity at week 4 of treatment compared to baseline.
The high-dose group showed a consistent decrease in pain intensity from week 1 to week 4 of administration. After four weeks of treatment, 32% of patients in the high-dose group achieved a reduction in pain intensity of 40% or more from baseline, which was more than twice as high as the 15% observed in the placebo group.
Overall, no significant safety concerns were identified, and the company evaluated the safety and tolerability as favorable. As in the Phase 1 trial, adverse events observed with four weeks of repeated dosing were primarily mild dizziness and nausea.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Vivogen representative stated, "Given that this Phase 2 clinical trial was an exploratory study conducted with approximately 30 patients per group, the results are meaningful," adding, "VVZ-2471 will be developed as a next-generation oral drug candidate targeting the treatment of chronic neuropathic pain, including postherpetic neuralgia, as well as drug addiction."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.